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Introduction
In parallel with enhanced survival rates of pediatric
Hodgkin’s lymphoma patients by current chemotherapy and
radiotherapy protocols, an increase in early and late complication
rates have also been noted. Common late complications of
childhood cancers after treatment include neurological, cardiac,
pulmonary and gonadal disorders, reduction in bone mass,
defective bone and soft tissue development, and increased 
susceptibility to secondary malignant tumors (1,2,3,4,5,6,7,8,9). 
Hyperthyroidism including Graves’ disease, thyroiditis,
hypothyroidism, thyroid nodules and thyroid cancers are the
most commonly encountered thyroid gland disorders that are
known to be related with radiotherapy (6,10,11,12,13).
The objective of this study was to evaluate thyroid function
in pediatric Hodgkin’s lymphoma patients in complete remission
with chemotherapy and radiotherapy.
Methods
In this retrospective study, we assessed the thyroid 
functions in 55 pediatric Hodgkin’s lymphoma patients in 
complete remission who were treated in the Department of
Pediatric Oncology at Uludag University Medical Faculty
between January 1995 and December 2008.  
ABSTRACT
Objective: Post-treatment endocrine disturbances are common in cancer
patients who have received radiotherapy or chemotherapy. The objective 
of this study was to evaluate the thyroid functions of long-term survivors of
pediatric Hodgkin’s lymphoma treated with chemotherapy and radiotherapy. 
Methods: Thyroid functions of 55 Hodgkin’s lymphoma patients (M/F:2.05/1)
in complete remission were evaluated retrospectively.
Results: The mean age of the patients at diagnosis was 10.35±4.09
(range: 2.83-17) years and the mean follow-up period was 5.54±3.68
(range: 0.92-13.92) years. All patients received chemotherapy; a total of
50 patients (90.9%) underwent radiotherapy, 42 (76.4%) of whom
received neck/mantle radiotherapy. Thyroid function tests were abnormal
in 14 (24.5%) patients and normal - in the remaining 41 (74.5%). A 
diagnosis of subclinical and overt hypothyroidism was made in 11 (78.6%)
and 3 (21.4%) patients with abnormal thyroid function tests, respectively.
Nearly one-fourth (21.4%) of all thyroid function disorders were detected
in the first year of follow-up. A statistically significant correlation was
found between the dose of mantle radiotherapy and thyroid function 
disorder (p=0.002). In addition, statistically significant correlations were
established between thyroid examination or thyroid ultrasonography 
findings and thyroid functions (p <0.001 or p=0.006, respectively). 
Conclusions: Radiation-induced thyroid disorders may develop in pediatric
Hodgkin’s lymphoma patients in complete remission starting as early as the
first year after treatment and are dose-dependent. Patients, particularly those
who have been exposed to radiotherapy of the neck, must be followed up
closely for occurrence of thyroid dysfunctions. 
K Ke ey y   w wo or rd ds s: : Hodgkin disease, children, late effect
C Co on nf fl li ic ct t   o of f   i in nt te er re es st t: : None declared
R Re ec ce ei iv ve ed d: : 14.03.2001 A Ac cc ce ep pt te ed d: : 23.04.2011Recurrence occurred only in 2 patients who received a 
second treatment regimen and were then followed up in 
complete remission. Physical and thyroid examination  findings,
thyroid stimulating hormone (TSH), free triiodothyronine (fT3),
free thyroxine (fT4), total T3, and total T4 levels, thyroid imaging
(ultrasonography and/or scintigraphy), thyroid antibody data,
serum thyroglobulin and calcitonin levels were obtained from
patient records and evaluated.
Age and gender of the patients, stage and histopathological
subgroup of the disease, chemotherapy protocols, number of
cycles, radiotherapy region and dose, and follow-up durations
were noted. Patients with hypothyroidism were divided into
two groups as subclinical hypothyroidism and overt 
hypothyroidism.
The study was approved by the local ethics committee.
The following four chemotherapy protocols were used: i)
ABVD (adriamycin 25 mg/m2 1st and 15th days, intravenously
(i.v.), bleomycin 10 mg/m2 1st and 15th days i.v., vinblastine 6
mg/m2 1st and 15th days i.v., dacarbazine 375 mg/m2 1st and
15th days i.v.); ii) COPP (cyclophosphamide 600 mg/m2 1st and
8th days i.v., vincristine 1.4 mg/m2 1st and 8th days i.v., 
procarbazine 100 mg/m2 1-14 days p.o., prednisolone 40
mg/m2 1-14 days p.o.), iii) MOPP (mechlorethamine 5 mg/m2
1st and 8th days i.v., vincristine 1.4 mg/m2 1st and 8th days i.v.,
procarbazine 100 mg/m2 1-14 days p.o., prednisolone 40
mg/m2 1-14 days p.o.), iv) MOPP/ABVD or COPP/ABVD hybrid
treatment protocol. 
The COPP, MOPP or hybrid protocols were applied to the
patients between 1995 and 1997, while ABVD treatment 
protocol was given after 1997. All subjects, except for those
who experienced recurrence, received 3-6 chemotherapy
cycles. 
Radiotherapy regions were grouped as: i) neck region and
mantle radiotherapy ii) mediastinum, iii) other regions. The
patients received a total dose of 2520 centigrays (cGy) mantle
radiotherapy with a daily dose of 180 cGy. The dose of 
radiotherapy was completed to 3060 or 3600 in patients with
remaining lymphadenopathy after standard dose 
chemotherapy and in those with residual disease after 
radiotherapy, respectively.
Serum total T3, total T4, fT3, fT4 and TSH levels were 
analyzed by Immulite 2000 autoanalyzer using 
chemiluminescent microparticle immunoassay (CMIA) method
(Abbott Laboratories).
The statistical analyses were performed using SPSS
(Statistical Package for the Social Sciences) for Windows 13.0
software. Comparisons of continuous variables in multiple
groups were made applying the Kruskal-Wallis test, while 
comparisons between two groups were made using the 
Mann-Whitney U test. Inter-group differences of categorical
variables were determined by the Pearson’s chi-square test and
Fisher’s exact test. Results were presented as mean±standard
deviation (SD) values. A p-value of less than 0.05 was 
considered statistically significant.
Results
Table 1 lists the demographic features of the 55 patients
included in this study. The patients were classified according to
their thyroid function tests as normal (group 1) and abnormal
(group 2). The total study population consisted of 37 males
(67.3%) and 18 females (32.3%); male/female ratio was 2.05/1.
Thyroid function tests were normal in 41 (74.5%) patients,
while thyroid dysfunction was present in 14 (25.5%) patients.
No statistically significant difference was found with regard to
thyroid dysfunction between genders.
The mean ages of the patients at diagnosis and when the
study was performed were 10.35±4.09 (range: 2.83-17) years
and 15.84±3.91 (range: 6.91-24) years, respectively. The 
mean follow-up duration was 5.54±3.68 (range 0.92-13.92)
years. No statistically significant difference was found with
regard to gender distribution or follow-up duration between
groups 1 and 2. 
Thyroid examination was normal (grade 0) in 40 (72.7%)
patients, while grade I, grade II, and grade III goiter was 
detected in 9 (16.4%), 5 (9.1%), and 1 (1.8%) patient, 
respectively. Thyroid ultrasonography  performed in 45 (81.8%)
out of 55 patients was normal in 41 (91.1%) and abnormal in 
4 (8.9%) patients (nodules in 3 patients and hypoechoic cyst in
1 patient). 
Thyroid functions were normal in 95% of patients with 
normal thyroid examination findings, in 22.2% of patients with
grade I goiter and in 20% of patients with grade II goiter. One
patient with grade III goiter had abnormal thyroid functions.
Thyroid functions were significantly correlated with thyroid
examination findings (p<0.001). 
Thyroid ultrasonography was performed in 87.8% and
64.3% of subjects in group 1 and 2, respectively. Thyroid 
90
Demirkaya M et al.
Thyroid Functions in Pediatric Hodgkin’s Lymphoma
Table 1. Demographic features of the patients
Thyroid functions
Normal Abnormal
Number of patients [n, (%)]  41 (74.5) 14 (25.5)
Gender [n, (%)]
Male 26 (70.3) 11 (29.7)
Female 15 (83.3) 3 (16.7)
Age at diagnosis 10.45±4.2 10.07±3.89
[(years), (mean ±SD)] (3.66-17) (2.83-16.41)
Age at time of study 16.1±4.11 15.07±3.27
[(years), (mean ±SD)]  (6.91-24) (10.08-20.91)
Mean follow-up duration    5.78±4.08 5.01±2.83
[(years), (mean ±SD)]  (0.92-16.25) (0.92-11.33)
SD: standard deviationfunctions were normal in 85.7% of patients with normal 
ultrasonographic findings; in contrast, thyroid dysfunction was
found in all 4 patients with abnormal ultrasonographic findings.
A significant correlation was observed between thyroid 
ultrasonography findings and thyroid functions (p=0.006). The 4
patients in group 2 who showed abnormal ultrasonographic
findings included 3 patients with nodules and one patient with
a 12x17 mm hypoechoic cystic degeneration on the right 
thyroid lobe. Hypothyroidism was present in all 4 patients.
Thyroglobulin levels in the case with hypoechoic cyst were
higher than normal and the patient underwent thyroid surgery.
The cyst was benign in nature on histopathological evaluation. 
As shown in Table 2, histopathological typing revealed that
the Hodgkin’s lymphoma was nodular sclerosing in 28 (50.9%)
patients, mixed-cell in 23 (41.8%) and lymphocyte-rich in 4
(7.3%) patients. According to the Hodgkin’s lymphoma staging,
13 (23.6%), 18 (32.7%), 19 (34.5%) and 5 (9.1%) patients were
classified as having stages I, II, III, and IV, respectively.
ABVD, COPP, and MOPP/ABVD hybrid protocols were
applied to 49 (89.1%), 2 (3.6%), and 4 (7.3%) patients, 
respectively. Three and 6 cycles of chemotherapy were given
to 50.9% and 49.1% of all patients, respectively.
Out of the 55 patients in our study, 50 (90.9%) received
radiotherapy, 42 (76.4%) of whom underwent neck/mantle
radiotherapy. Twenty-two (52.4%), 14 (33.3%), and 6 (14.3%)
patients received a total dose of 2520 cGy, 3060 cGy, and 3600
cGy neck/mantle radiotherapy, respectively. Twenty-two
(52.4%) out of 42 patients who received neck/mantle 
radiotherapy also received radiotherapy to other regions, while
the remaining 20 (47.6%) patients did not. 
Statistical analysis revealed no differences with regard to
thyroid function among the different histopathological groups,
nor among the various stage or chemotherapy groups. There
were also no differences detected among patients who 
were exposed to 3 or to 6 cycles of treatment. Exposure or 
non-exposure to radiotherapy or to radiotherapy to the
neck/mantle region also did not appear to lead to differences in
thyroid function. On the other hand, statistically significant 
differences were found regarding thyroid dysfunction among
patients receiving different doses of neck/mantle radiotherapy.
Thyroid function was normal in 72.7%, 92.9%, and 16.7% of
patients who received a total dose of 2520 cGy, 3060 cGy, and
3600 cGy neck/mantle radiotherapy, respectively. However,
binary comparisons of the three doses revealed statistically 
significant differences between the 2520 cGy dose and the
3600 cGy dose (p=0.022) and also between the 3060 cGy dose
and 3600 cGy dose (p=0.002).
Subclinical and overt hypothyroidism was diagnosed in 
11 (78.6%) and 3 (21.4%) patients with abnormal thyroid 
function tests, respectively. Table 3 lists the features in 
individual patients with abnormal thyroid function tests. Thyroid
dysfunction was detected after the first, second, third, fourth
and fifth year of treatment in 3, 2, 3, 4 and 2 patients, 
respectively. No statistically significant correlation was found
between time passed after treatment and thyroid dysfunction. 
Discussion
In parallel to enhanced survival rates of pediatric Hodgkin’s
lymphoma patients by current chemotherapy and radiotherapy
protocols, an increase in early and late complication rates was
also noted (14,15,16). The risk of thyroid disorder development
was found to be 52% and 67% after 20 and 26 years of 
survival, respectively, in a study including 1787 patients with
Hodgkin’s lymphoma (14). We found a thyroid disorder rate of
25.5% within a mean follow-up duration of 5.54 years in our
study group of 55 patients, all in complete remission following
chemotherapy and radiotherapy. Of the 14 patients who
showed abnormal thyroid function, 78.6% were diagnosed as
subclinical and 11.4% as overt hypothyroidism. 
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Table 2. Clinical characteristics of the patients
Thyroid functions
Normal (n=41) Abnormal (n=14)
Histopathology [n, (%)] 
nodular sclerosing   20 (71.4) 8 (28.6)
mixed-cell  17 (73.9) 6 (26.1)
lymphocyte-rich 4 (100) -
Stage [n, (%)] 
I  11 (84.6) 2 (15.4)
II  12 (66.7) 6 (33.3)
III  13 (68.4) 6 (31.6)
IV 5  (100) -
Chemotherapy [n, (%)] 
ABVD  35 (71.4) 14 (28.6)
COPP 2  (100) -
MOPP/ABVD 4 (100) -
Number of cycles [n, (%)] 
3 cycles 20 (71.4) 8 (28.6)
6 cycles 21 (77.8) 6 (22.2)
Radiotherapy [n, (%)]  36 (72) 14 (28)
Neck/mantle region [n, (%)]  30 (71.4) 12 (28.6)
Neck/mantle dose* [n, (%)]         
2520 cGy 16 (72.7) 6 (27.3)
3060 cGy 13 (92.9) 1 (7.1)
3600 cGy 1 (16.7) 5 (83.3)
* p<0.05, SD: standard deviation, ABVD: adriamycin, bleomycin, vinblastine, 
dacarbazine, COPP: cyclophosphamide, vincristine, procarbazine, prednisolone,
MOPP: mechlorethamine, vincristine, procarbazine, prednisolone
cGy: centigraysSubclinical hypothyroidism following exposure to 
radiotherapy has been reported to have a high incidence in
Hodgkin’s patients (17). Hunger et al (18) detected subclinical
chemical hypothyroidism in 9 (16%) out of 57 patients who
received a combination of chemotherapy and low-dose 
radiotherapy in their study with a mean follow-up duration of 6.7
years. In another study (19), subclinical hypothyroidism was
found in 22 (63%) out of 35 patients with Hodgkin’s lymphoma
who received mantle radiotherapy; some of these patients
reportedly recovered within time. Periodical thyroid function
tests revealed altered levels of at least one thyroid hormone.
Elevation in TSH level was the most commonly encountered
disorder. In one study (20), a high TSH was reported in 29
(50%) out of 58 patients who had received chemotherapy and
low-dose (15-25 Gy) mantle radiotherapy. In our study, we also
observed a significant correlation between thyroid dysfunction
and dose of the neck/mantle radiotherapy. 
Radiotherapy dose, which was 44-45 Gy previously, was
reduced to 15-25.5 Gy due to late complications (1). In a study
(21) on 119 Hodgkin’s lymphoma patients, TSH levels were
found to be elevated in 17% and 78% of those who received
low-dose (lower than 2600 rad) and high-dose (higher than 2600
rad) mantle radiotherapy to the neck, 
respectively. Since thyroid dysfunction occurred 18 and 31
months after low- and high-dose radiotherapy, respectively, it is
generally stated that it takes a time period of 3 to 5 years for
thyroid function to be affected. In another study (6) with a mean
follow-up duration of 30 years, thyroid dysfunction, the most
common (17.1%) of which was hypothyroidism (p=0.0001),
was detected in 34% of 1791 Hodgkin’s lymphoma patients
who received chemotherapy and radiotherapy; the risk of
hypothyroidism was increased by high-dose radiotherapy,
advanced diagnosis age and female gender. Hyperthyroidism
was detected in 5% of these patients - an 8-fold increased risk
compared with controls (p=0.0001). The risk of thyroid nodule
development was 27-fold that of controls after a mean latent
period of 14 years in this same study and the risk of nodule
development was correlated with high dose radiotherapy 
(higher than 2500 cGy) and female gender. 7% of the nodules
were of malignant nature. In addition, thyroid cancer was found
in 20 survivors in that study, which is 18-fold of that expected
in a community.
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Table 3. Features of patients with overt and subclinical hypothyroidism
Age at Gender Stage Chemotherapy Neck/mantle  Thyroid  Thyroid  Thyroid
diagnosis protocol/number  RT  examination USG dysfunction 
(years) of cycles dose (cGy) grade time
Overt 
hypothyroidism
Patient 1     16.4 F 1 ABVD/3 2520 1 - 1st year
Patient 2 9.8 M 2b ABVD/3 3060 1 normal 5th year
Patient 3 10.8 M 1 ABVD/3 2520 1 nodule 3rd year
Subclinical
hypothyroidism
Patient 4 13.8 M 3sb ABVD/6 2520 1 normal 2nd year 
Patient 5 14.6 M 3 ABVD/6 3600 1 - 4th year
Patient 6  11.6 M 2b ABVD/3 3600 2 nodule 4th year
Patient 7 8.9 M 2 ABVD/3 3600 2 normal 3rd year 
Patient 8 9.2 F 2 ABVD/3 2520 2 normal 1st year 
Patient 9 2.8 M 3s ABVD/6 - 1 - >5th year
Patient 10 14.8 M 3sb ABVD/6 - 0 - 3rd year 
Patient 11 6.5 M 2 ABVD/3 2520 1 nodule  4th year
Patient 12 6.7 M 3s ABVD/6 3600 0 - 1st year 
Patient 13 9.2 M 3s ABVD/6 3600 2 normal 2nd year
Patient 14 5.8 F 2 ABVD/3 2520 3 cyst >5th year
ABVD: adriamycin, bleomycin, vinblastine, dacarbazine, F: female, M: male, RT: radiotherapy, cGy: centigraysIn a study (14) on 1677 patients with Hodgkin’s lymphoma
who received radiotherapy to the thyroid gland region, at least
one nodule was detected in 2.6% of them. The risk of thyroid
nodule development was found to be increased 27-fold in a
controlled study after a mean latent period of 14 years. 7% of
the nodules were of malignant nature.  Independent risk factors
were reported as female gender and high dose (higher than 25
Gy) of radiotherapy (6). The risk of benign or malignant thyroid 
disease development subsequent to chemotherapy and 
radiotherapy is reported to be increased 1.74- or 36.4-fold,
respectively. The length of duration after treatment and the age
at which the treatment was initiated increase this risk. Although
radiotherapy is significantly correlated with such risks, the risk
caused by chemotherapy is not clear. However, it is generally
accepted that a combination of chemotherapy and radiotherapy
further enhances the risk of benign or malignant thyroid 
disease (22). 
A study (23) on 1380 patients with Hodgkin’s lymphoma
reported thyroid neoplasm in 19 (1.4%) patients within a mean
follow-up period of 15.3 years (range: 4.2-29.7 years).
Radiotherapy, chemotherapy and a combination of radiotherapy
plus chemotherapy were applied to 5 (26%), 1 (5%) and 13
(69%) patients, respectively. Cumulative incidence for 
secondary malignancy was calculated as 10.6% and 26.3% on
the 20th and 30th years, respectively. In another study (24) 
conducted between 1960 and 1990, thyroid malignancies were
detected in 14 (1.5%) out of 930 patients with Hodgkin’s 
lymphoma within a mean follow-up period of 14.4 (range: 
8.5-23) years. Another study (25) reported that the overall
cumulative 10- and 20-year second malignancy rates were
2.45% and 7.29%, respectively, in 358 pediatric Hodgkin’s 
lymphoma patients, and that only one patient who received
chemotherapy alone developed thyroid malignancy on the 13th
year after treatment. Acharya et al (12) reported that 18 out of
33 patients with pediatric Hodgkin’s lymphoma developed 
thyroid neoplasm after a mean mantle radiotherapy dose of
2400 cGy (range: 1000-4200 cGy) to the neck within a mean
period of 13 (range 6.2-30.1) years and that 39% of those 
neoplasms were of malignant nature (13 papillary carcinoma
and 2 follicular carcinoma). Another study (26) found that 10%
of 67 patients developed thyroid nodules of malignant nature
16.2 years after completion of radiotherapy with an average 35
Gy dose. 
In our study, we detected thyroid nodules in 4 (7.3%)
patients within an average follow-up period of 5.5±3.7 years.
One of these patients received surgery and the nodule was
reported to be benign in nature. One reason why we did not
encounter malignant thyroid nodules in our patients might be
the relatively short duration of follow-up after completion of
treatment.
In conclusion, our study shows that thyroid dysfunction
occurs in approximately one-fourth of pediatric Hodgkin’s 
lymphoma patients within an average period of 5.5 years after
completion of treatment. Our findings also demonstrate that
thyroid functions can be affected as early as the first year after
completion of treatment. Thyroid dysfunction was found to 
statistically correlate with the dose of neck/mantle radiotherapy.
The reason why the rate of thyroid dysfunction in our study was
smaller than those in other reports could be that we applied a
lower dose as mantle radiotherapy. It is also known that the
rate of detection of thyroid nodules increases with duration of
follow-up. Thus, periodic evaluation of the thyroid gland in
Hodgkin’s lymphoma patients who received radiotherapy and
chemotherapy needs to be started at an early period after 
treatment and continued for many years. 
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